Clinical Trials in Depth
Clinical trials, also called research studies, may offer good treatment options for some people with
IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
Clinical trials, also called research studies, may offer good treatment options for some people with
Leslie S. Kean, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center, discusses findings from her analysis of the International Blood and Marrow Transplant Research Database, which led to the recent FDA approval of abatacept for the prevention of acute graft-vs-host disease (GVHD) in adult and pediatric patients. The data suggest improved overall survival with the immunosuppressant abatacept in combination with a calcineurin inhibitor and methotrexate following 7/8 HLA–matched unrelated allogeneic hematopoietic stem cell transplantation (Abstract 3912).
Amphiregulin (AREG) may represent a useful longitudinal monitoring biomarker for patients with life-threatening acute graft-vs-host disease (GVHD), according to a sample of 2 prospective clinical trials that was presented at the 2021 ASH Annual Meeting. Specifically, patients with a high baseline of AREG are at an increased mortality risk and, therefore, should be monitored consistently during serial assessments.
Today, the U.S. Food and Drug Administration approved Orencia (abatacept) for the prophylaxis (prevention) of acute graft versus host disease (aGVHD), a condition that occurs when donor bone marrow or
Understanding Low Risk MDS 2021 Winter Patient Family Conference
Adrienne Phillips, MD, MPH
Understanding Aplastic Anemia 2021 Winter Patient Family Conference
Anna Koget, DO
Understanding Low Risk MDS 2021 Fall Patient Family Conference
Suresh Balasubramian, MD, Karmanos Cancer Center
Understanding Aplastic Anemia 2021 Fall Patient Family Conference
Daria Babushok, MD, PhD, Penn Medicine
Managing the Side Effects of Bone Marrow Failure - Summer 2021 Conference
Eric Padron, MD, Moffitt Cancer Center
Diagnosing Bone Marrow Failure Diseases - Summer 2021 Conference
Amy Duffield, MD, PhD, Memorial Sloan Kettering
8th Seattle Patient Conference: Ask an Expert
H. Joachim Deeg, MD
8th Seattle Patient Conference - Living Well with MDS/MPN
Krisstina Gowin, DO, University of Arizona
What Are My Options with High Risk MDS/AML: Spring 2021 Conference (Apr 2021)
Nathan Punwani, MD, Cedars-Sinai
What's My Mutation? Understanding the Risks for Low/Moderate Risk MDS Patients: Spring 2021 Conference (Apr 2021)
Tiffany Tanaka, MD, UC San Diego Health
The FDA has approved ruxolitinib (Jakafi) for the treatment of patients 12 years and older with chronic
